Association between pathologic response and survival after neoadjuvant therapy in lung cancer
Open accessThe DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Neoadjuvant immunotherapy plus chemotherapy improves event-free survival (EFS) and pathologic complete response (0% residual viable tumor (RVT) in primary tumor (PT) and lymph nodes (LNs)), and is approved for treatment of resectable lung cancer. Pathologic response assessment after neoadjuvant therapy is the potential analog to radiographic response for advanced disease. However, %RVT thresholds beyond pathologic complete response and major pathologic response (≤10% RVT) have not been explored. Pathologic response was prospectively assessed in the randomized, phase 3 CheckMate 816 trial (NCT02998528), which evaluated neoadjuvant nivolumab (anti-programmed death protein 1) plus chemotherapy in patients with resectable lung cancer. RVT, regression and necrosis were quantified (0–100%) in PT and LNs using a pan-tumor scoring system and tested for association with EFS in a prespecified exploratory analysis. Regardless of LN involvement, EFS improved with 0% versus >0% RVT-PT (hazard ratio = 0.18). RVT-PT predicted EFS for nivolumab plus chemotherapy (area under the curve = 0.74); 2-year EFS rates were 90%, 60%, 57% and 39% for patients with 0–5%, >5–30%, >30–80% and >80% RVT, respectively. Each 1% RVT associated with a 0.017 hazard ratio increase for EFS. Combining pathologic response from PT and LNs helped differentiate outcomes. When compared with radiographic response and circulating tumor DNA clearance, %RVT best approximated EFS. These findings support pathologic response as an emerging survival surrogate. Further assessment of the full spectrum of %RVT in lung cancer and other tumor types is warranted. ClinicalTrials.gov registration: NCT02998528 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evolving experience from the use of systemic anticancer therapy in solid tumours suggests that a pathologically demonstrated response in resected specimens predicts improved chances of complete remission in patients with various oncological diagnoses, including breast cancer, non-small-cell lung cancer, and bladder cancer.15–17”
From Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis (2024) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These findings are in line with what has been previously shown in patients with non-small-cell lung cancer, whereby a population of patients with early-stage disease undergoing neoadjuvant chemotherapy combined with ICI showed a similar polarisation of pathological responses.16”
From Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis (2024) · cites this paper as [16]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“It also serves as a guide for the treating oncologist 27 .”
BackgroundGoldstraw, P., Chansky, K., Crowley, J., Rami-Porta, R., Asamura, H., Eberhardt, W. E. E., Nicholson, A. G., Groome, P., Mitchell, A., Bolejack, V., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.09.009 · Cited by 4,607 · cited 1×
“Previous scoring systems for pathologic response to chemotherapy as well as American Joint Committee on Cancer pathologic downstaging require pathologic confirmation of pretreatment nodal disease 36 , which is subject to sampling error.”
MethodTime‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & Pepe, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,854
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, P. M., Spicer, J., Lu, S., Provencio, M., Mitsudomi, T., Awad, M. M., Felip, E., Broderick, S. R., Brahmer, J. R., Swanson, S. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2202170 · Cited by 2,825 · cited 6×
“A list of investigators and study sites was previously published 19 .”
BackgroundMethodResultInfluentialSelf-citationNeoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Self-citationSurrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651 · cited 1×
“In contrast to correlates, surrogates not only associate with outcome, but also manifest overall treatment effect on the clinical outcome 24,25 .”
BackgroundChalabi, M., Fanchi, L. F., Dijkstra, K. K., Van den Berg, J. G., Aalbers, A. G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G. L., Snaebjornsson, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0805-8 · Cited by 1,417 · cited 1×
“…is independent of disease location, for example, primary tumor (PT), lymph node (LN) or distant metastasis 7,8 , and scores RVT from 0 to 100%. irPRC for the assessment of %RVT has been used in multiple phase 1 and 2 trials evaluating neoadjuvant immunotherapy across diverse tumor types 9–18 .”
MethodPerioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
Wakelee, H., Liberman, M., Kato, T., Tsuboi, M., Lee, S.-H., Gao, S., Chen, K.-N., Dooms, C., Majem, M., Eigendorff, E., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2302983 · Cited by 1,180 · cited 1×
“Since the first report, periadjuvant chemotherapy plus immunotherapy regimens have shown efficacy in this patient population 20,21 .”
BackgroundSelf-citationNeoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001 · cited 1×
“Neoadjuvant systemic immunotherapy offers the advantage of enhanced priming of the immune system while higher levels of tumor antigens are present, leading to improved immune surveillance of micrometastatic disease 4 .”
BackgroundSelf-citationIonic immune suppression within the tumour microenvironment limits T cell effector function
Eil, R., Vodnala, S. K., Clever, D., Klebanoff, C. A., Sukumar, M., Pan, J. H., Palmer, D. C., Gros, A., Yamamoto, T. N., Patel, S. J., et al. (2016) · Nature · doi:10.1038/nature19364 · Cited by 678 · cited 1×
“Preclinical studies have reported the adverse effect of necrosis on T cell effector function 34 , and a recent study in renal cell carcinoma showed that necrosis attenuated the survival benefit of TILs in patients receiving anti-PD-1 (ref.”
Background
Cited by
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
Forde, P. M., Spicer, J. D., Provencio, M., Mitsudomi, T., Awad, M. M., Wang, C., Lu, S., Felip, E., Swanson, S. J., Brahmer, J. R., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502931 · Cited by 247
Self-citationSpicer, J. D., Cascone, T., Wynes, M. W., Ahn, M.-J., Dacic, S., Felip, E., Forde, P. M., Higgins, K. A., Kris, M. G., Mitsudomi, T., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.06.010 · Cited by 161
Self-citationA single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer
Liu, Z., Yang, Z., Wu, J., Zhang, W., Sun, Y., Zhang, C., Bai, G., Li, Y., Fan, H., Chen, Y., et al. (2025) · Cell · doi:10.1016/j.cell.2025.03.018 · Cited by 198
Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial
de Gooyer, P., Verschoor, Y. L., van den Dungen, L. D. W., Balduzzi, S., Marsman, H. A., Foppen, M. H. G., Grootscholten, C., Dokter, S., den Hartog, A. G., Verbeek, W. H. M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03250-w · Cited by 149
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 160
Metadata
- Authors
- Deutsch, J. S., Cimino-Mathews, A., Thompson, E., Provencio, M., Forde, P. M., Spicer, J., Girard, N., Wang, D., Anders, R. A., Gabrielson, E., Illei, P., Jedrych, J., Danilova, L., Sunshine, J., Kerr, K. M., Tran, M., Bushong, J., Cai, J., Devas, V., Neely, J., Balli, D., Cottrell, T. R., Baras, A. S., & Taube, J. M.
- Affiliations
- Johns Hopkins University (US)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- McGill University Health Centre (CA)
- Institut Curie (FR)
- Aberdeen Royal Infirmary (GB)
- Bristol-Myers Squibb (United States) (US)
- Queen's University (CA)
- Corresponding author
- Taube, Janis M.
- ORCID
- Deutsch, Julie Stein
- Thompson, Elizabeth
- Provencio, Mariano
- Forde, Patrick M.
- Spicer, Jonathan
- Girard, Nicolas
- Wang, Daphne
- Anders, Robert A.
- Gabrielson, Edward
- Illei, Peter
- Jedrych, Jaroslaw
- Danilova, Ludmila
- Sunshine, Joel
- Bushong, Judith
- Neely, Jaclyn
- Balli, David
- Cottrell, Tricia R.
- Baras, Alex S.
- Taube, Janis M.
- Venue
- Nature Medicine
- Published
- 2023-10-30
- Volume
- 30
- Issue
- 1
- Pages
- 218-228
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC10803255
- OpenAlex
- W4388033556
- Cited by
- 198
- References
- 41
- Citations by year
- 2026: 63 · 2025: 80 · 2024: 54 · 2023: 1
- FWCI
- 36.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- Mesothelioma Applied Research Foundation
- LUNGevity Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Regeneron Pharmaceuticals
- Society for Immunotherapy of Cancer
- Mark Foundation For Cancer Research
- F-star Therapeutics
- G1 Therapeutics
- Canadian Association of Thoracic Surgeons
- Ono Pharmaceutical
- National Institutes of Health
- Genentech
- National Cancer Institute (R01CA142779)
- Congressionally Directed Medical Research Programs
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung cancer, neoadjuvant therapy, pathological response, residual viable tumor, event-free survival, nivolumab, immune checkpoint inhibitors, chemotherapy, resectable lung cancer, lymph node involvement, circulating tumor DNA, surrogate endpoints, CheckMate 816
- MeSH terms
- Nivolumab, Progression-Free Survival, Pathologic Complete Response, Antineoplastic Combined Chemotherapy Protocols, Humans, Lung Neoplasms, Randomized Controlled Trials as Topic, Treatment Outcome, Clinical Trials, Phase III as Topic, Neoadjuvant Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association between pathologic response and survival after neoadjuvant therapy in lung cancer. https://app.cochat.ai/papers/10.1038/s41591-023-02660-6
- The paper
- Deutsch, J. S., Cimino-Mathews, A., Thompson, E., Provencio, M., Forde, P. M., Spicer, J., Girard, N., Wang, D., Anders, R. A., Gabrielson, E., Illei, P., Jedrych, J., Danilova, L., Sunshine, J., Kerr, K. M., Tran, M., Bushong, J., Cai, J., Devas, V., . . . Taube, J. M. (2024). Association between pathologic response and survival after neoadjuvant therapy in lung cancer. Nature Medicine. https://doi.org/10.1038/s41591-023-02660-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.